The t(11;14)(q13;q32) is seen in 15-20% patients with multiple myeloma (MM). In general, it is not associated with worse outcome. We studied the impact of t(11;14)(q13;q32) on the outcome of patients with MM who received high-dose chemotherapy followed by an autologous hematopoietic stem cell transplantation (auto-HCT). Eligible patients underwent high-dose chemotherapy followed by auto-HCT at the M.D. Anderson Cancer Center between February 2000 and August 2010, and had conventional cytogenetic (CC) or fluorescent in situ hybridization (FISH) results available prior to auto-HCT (n=993). The cohort is divided into three groups of patients: (1) normal (diploid by CC, and negative by FISH; n=869); (2) t(11;14)(q13;q32) by CC or FISH (n=27); and (3) high-risk (HR) abnormalities by CC or FISH (n=97). Of the 27 patients with t(11;14)(q13;q32), 18 had isolated t(11;14)(q13;q32) while 9 patients had concurrent HR abnormalities. The primary objective was to compare the outcome of patients with t(11;14)(q13;q32) to patients with diploid or HR markers by CC or FISH studies. Median follow up in surviving patients was 37 months. 3-year PFS for normal, t(11;14)(q13;q32) and HR groups were 47%, 27% and 13%, respectively (p=<0.00001). 3-year OS for normal, t(11;14)(q13;q32) and HR groups were 83%, 63% and 34%, respectively (p=<0.00001). On multivariate analyses, t(11;14)(q13;q32) and HR abnormalities by CC or FISH, and relapsed disease at auto-HCT were associated with shorter PFS, while t(11;14)(q13;q32) and HR abnormalities by CC or FISH, β2 microglobulin of >3.5 and relapsed disease at auto-HCT were associated with shorter OS. In conclusion, patients with t(11;14)(q13;q32) had worse outcome than patients with normal CC or FISH, but better than patients with HR markers by CC or FISH studies.